The European Commission has approved the marketing authorization for RESPIVAC® aMPV, a lyophilized vaccine for ocular or nasal suspension in drinking water against avian metapneumovirus.

RESPIVAC® aMPV replaces the current HIPRAVIAR® SHS, which is currently registered in countries in Asia and Latin America. The approval of this product marks a significant advancement in the prevention of avian metapneumovirus in Europe, due to the increasing prevalence of the disease and its impact on the productivity indices of the poultry industry.

One of the special features of this vaccine is its registration for use during the laying period, making it unique in the market. Vaccinating during the laying period offers greater flexibility and prolonged protection in the vaccination plan against avian metapneumovirus. This vaccine is also registered for broiler chickens, a sector where increasing awareness of this disease is crucial. Registration for turkeys will also be obtained in 2025. 

The commercialization of RESPIVAC® aMPV is already underway in the European region, where a series of local events will be held over the coming months to introduce the vaccine.